VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021
November 04 2021 - 8:00AM
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical
company committed to developing a new generation of medicines with
the potential to go beyond the current standard of care for
anxiety, depression, and other central nervous system (“CNS”)
disorders, today announced that it will host a conference call and
webcast, reporting its financial results for the quarter ended
September 30, 2021 and reviewing recent accomplishments and
anticipated upcoming milestones, on Wednesday, November 10,
2021 at 5:00 p.m. Eastern Time.
Event: VistaGen Therapeutics Fiscal Year
2022 Second Quarter Financial Results and Recent Developments
Conference Call and WebcastDate: Wednesday,
November 10, 2021Time: 5:00 p.m. Eastern Time
U.S. Dial-in (Toll
Free): 1-877-407-9716International Dial-in
(Toll): 1-201-493-6779Conference
ID: 13724394Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1505931&tp_key=4eabb07e30
A live audio webcast of the conference call will be
available. Participants should access this webcast site 10
minutes before the start of the call. In addition, a telephone
playback of the call will be available after
approximately 8:00 p.m. Eastern Time on Wednesday,
November 10, 2021. To listen to the replay, call toll free
1-844-512-2921 within the United States or 1-412-317-6671
when calling internationally (toll). Please use the replay PIN
number 13724394.
About VistaGenVistaGen is a biopharmaceutical
company committed to developing and commercializing innovative
medicines with the potential to go beyond the current standard of
care for anxiety, depression, and other CNS disorders. Each of
VistaGen's CNS drug candidates has a differentiated profile and
therapeutic potential in multiple CNS markets. For more
information, please visit www.VistaGen.com and connect with
VistaGen on Twitter, LinkedIn, and Facebook.
VistaGen Company Contacts
Media:
Mark McPartlandVice President, Corporate DevelopmentPhone: (650)
577-3606Email: IR@vistagen.com
Christy CurranSam Brown Inc.Phone: (615) 414-8668Email:
ChristyCurran@sambrown.com
Investor:
Mark FlatherVice President, Investor RelationsPhone: (650)
577-3617Email: IR@vistagen.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024